After activation, CD4 + Th cells diff erentiate into distinct eff ector subsets that are characterized by their unique cytokine expression and immunoregulatory function ( 1, 2 ) . A novel Th subset -termed Th IL-17 , Th17, or infl ammatory Th -has been recently identifi ed as a distinct Th lineage that mediates tissue infl ammation ( 3 -5 ) . Th17 diff erentiation is initiated by TGF-␤ and IL-6 ( 4, 6, 7 ), and reinforced by IL-23 ( 8 ) and IL-21 ( 9 -11 ) , in which STAT3 and two orphan nuclear receptors, ROR ␣ and ROR ␥ , mediate the lineage specifi cation ( 8, 12 -14 ) . Despite rapid progress in understanding the molecular programs that govern Th17 diff erentiation, it is not clear how their proliferation, and ultimately function, are regulated in the context of immune responses and diseases.
Th cell activation and diff erentiation requires not only the recognition of the antigen -MHC class II complex by the cognate TCR but also co-stimulatory signals. Previous experiments have indicated diff erential co-stimulatory regulation of Th1 and Th2 cell function ( 15 ) . Over the past decade, our knowledge of how diff erent ligand -receptor pairing interactions contribute to T cell co-stimulation has been steadily expanded. Most of these pairs belong to either the B7-type molecules that bind CD28-like Ig superfamily receptors, or the TNF superfamily ligands that engage their receptor counterparts in the TNFR family ( 16 ) . Although we have previously shown essential roles of CD28 and inducible co-stimulator in Th17 diff erentiation ( 17, 18 ) , the functional contribution of TNF and TNFR family members in regulating Th17 cell function is poorly understood.
Within the TNF family, CD40L, OX-40L, LIGHT, CD27L (CD70), and 4-1BBL have well-established functions in T cell activation and diff erentiation ( 16, 19 ) . Recent evidence suggests that another TNF family member, TL1A (Tnfsf15), also plays a role in T cell regulation. TL1A was fi rst identifi ed as a protein expressed on human endothelial cells and up-regulated in response to TNF-␣ and IL-1 ␣ ( 20 ), although an earlier study only identifi ed an irregularly spliced transcript. Subsequently, full-length TL1A was cloned, and expression of TL1A by human tissue macrophages, lamina propria T cells and plasma cells, and Fc ␥ R-activated peripheral blood (PB) monocytes and monocyte-derived DCs was demonstrated ( 21 -24 ) . TL1A binds death receptor 3 (DR3; also called TNFRSF25), a death domain -containing TNFR family member that signals via NF-B ( 25, 26 ) . DR3 expression is signifi cantly increased upon T cell activation and was initially thought to be restricted to lymphocytes ( 27 ) . However, recent data have expanded the number of cell types that express DR3 to also include NK cells, macrophages, and endothelial cells ( 22, 28, 29 ) . Although DR3-defi cient mice exhibit a partial impairment in the negative selection of thymocytes ( 30 ) , the impact of DR3 defi ciency on immune function has not been further explored. TL1A also binds to DcR3 ( 20 ) , a decoy receptor for TL1A, LIGHT, and FasL that is present in humans but not mice ( 31 ) , suggesting additional complexity in the role of this pathway in humans.
Several lines of evidence point to a role for TL1A in modulating T cell activation. Under conditions of suboptimal anti-CD3/CD28 stimulation, TL1A increases IL-2 -driven proliferation and IFN-␥ and GM-CSF production by human PB T cells, and in vivo administration of recombinant TL1A enhances mouse graft-versus-host reactions ( 20 ) . Thus, despite the presence of a death domain in DR3, binding of TL1A to DR3 on T cells provides a co-stimulatory signal ( 20 ) . TL1A also synergizes with IL-12 and IL-18 in stimulating TCR-independent secretion of IFN-␥ by human PB CD4 + memory T cells ( 29, 32 ) . The ability of TL1A to co-stimulate IFN-␥ secretion and the association of TL1A expression with areas of active infl ammation in Crohn ' s disease have led to the hypothesis that TL1A acts as a Th1-polarizing cytokine ( 21, 29, 32 ) . However, it was more recently shown that TL1A acted preferentially to enhance TCRstimulated proliferation of memory CD4 + T cells ( 33 ) , which was associated with an increased capacity of memory T cells to express IFN-␥ .
In the current study, we found that full-length DR3 expression is selectively elevated in Th17 cells and mediates their development and proliferation. Defi ciency in TL1A in DCs substantially reduced their ability in supporting Th17 diff erentiation and proliferation. Consistently, TL1A KO animals exhibited decreased Th17 generation in vivo and reduced disease severity upon induction of experimental autoimmune encephalomyelitis (EAE). Additionally, the absence of TL1A in recipient mice also resulted in reduced severity of EAE disease induced by adoptive transfer of autoreactive Th17 cells.
Collectively, these observations demonstrate that DR3 -TL1A Because TL1A has been shown to enhance proliferation and IFN-␥ secretion in CD4 + memory T cells ( 21, 33 ) , we examined the eff ect of TL1A on in vitro -diff erentiated Th1 and Th17 cells. Th1 and Th17 cells were incubated with a titrating dose of anti-CD3 and in the presence or absence of TL1A, and proliferation was measured by [ 3 H]thymidine incorporation. Culture supernatants were analyzed for IFN-␥ or IL-17 production by ELISA. As shown in Fig. 3 A , TL1A did not aff ect the proliferation or IFN-␥ production by Th1 eff ector cells. However, addition of TL1A greatly enhanced the proliferation of Th17 cells, especially at lower concentrations of anti-CD3 stimulation ( Fig. 3 B ) . More signifi cantly, in the absence of TCR stimulation, TL1A treatment did not enhance the proliferation of Th1 cells, whereas the proliferation of Th17 cells was greatly increased ( Fig. 3, A and B ) . Despite increased proliferation upon TL1A stimulation, IL-17 production was not increased under these conditions in the culture supernatants ( Fig. 3, A and B , bottom) or by intracellular staining (Fig. S1 , available at http://www.jem.org/ cgi/content/full/jem.20071364/DC1), suggesting that the primary function of the TL1A -DR3 pathway in Th17 cells may be to enhance cellular proliferation.
Because TL1A alone induced Th17 cell proliferation, we further analyzed the proliferation of Th17 cells at diff erent concentrations of TL1A. As shown in Fig. 3 C , proliferation of Th17 cells was greatly enhanced with increased concentration of Fc-TL1A, whereas the proliferation of Th1 cells remained unchanged even at the highest concentration (1 μ g/ml) of TL1A. Collectively, these results revealed a previously unknown and specifi c regulation of Th17 cells by the TL1A -DR3 interaction.
Because TGF-␤ also induces Foxp3 expression in activated T cells, we examined whether T reg cells expressed DR3. Interestingly, both naturally occurring T reg (n -T reg) and TGF-␤ -induced T reg (i -T reg) cells up-regulated DR3 expression ( Fig. 1, D and E ) . However, the full-length variant 1 represents a much higher proportion of the total DR3 isoforms expressed in Th17 cells as compared with n -T reg or i -T reg cells, supporting the preferential involvement of TL1A -DR3 interaction in regulating Th17 cell function.
TL1A stimulation regulates Th17 development and proliferation
To establish the potential biological relevance of DR3 expression on Th17 cells, we fi rst tested the eff ect of recombinant Fc-TL1A protein on Th17 diff erentiation, proliferation, and cytokine expression. Naive CD4 + T cells were activated with plate-bound anti-CD3/CD28 in the presence or absence of Fc-TL1A and in the presence of TGF ␤ + IL-6 or Th17 diff erentiation conditions. In comparison to cells treated with a control Fc-containing protein, Fc-TL1A enhanced IL-2 secretion ( Fig. 2 A ) . It has been recently shown that IL-2 signaling inhibits Th17 diff erentiation in a STAT5-dependent manner ( 34 ) . Consistently, percentages of IL-17 -producing cells were decreased by 40% in T cells diff erentiated in the presence of Fc-TL1A ( Fig. 2 B ) . However, upon treatment with an anti -IL-2 antibody, Fc-TL1A enhanced the diff erentiation of Th17 cells by 35% under TGF ␤ + IL-6 conditions and 20% under Th17 conditions ( Fig. 2 B ) . These results suggest that in the absence of IL-2 signaling, TL1A -DR3 interaction could function to enhance the diff erentiation of Th17 cells from naive T cells. 
TL1A-defi cient DCs exhibit reduced potency to induce Th17 differentiation and proliferation
Because Fc-TL1A enhanced the diff erentiation and proliferation of Th17 cells, we tested the impact of TL1A defi ciency in APCs on the diff erentiation of naive T cells into Th17 cells. LPS-stimulated bone marrow -derived DCs (BMDCs) from WT and TL1A KO mice were pulsed with OT-II peptide and used for activating naive OT-II CD4 T cells under Th1 and Th17 diff erentiation conditions. The development of eff ector cells was monitored by intracellular cytokine staining for IL-17 and IFN-␥ on day 6 after stimulation. As shown in Fig. 5 , diff erentiation of Th1 cells was not aff ected because of TL1A defi ciency; however, when OT-II CD4 T cells were diff erentiated with KO BMDCs, we observed a modest, yet reproducible, decrease in the percentage of Th17 cells generated ( Fig. 5 ) . These results are in agreement with our earlier in vitro results on the diff erentiation of naive CD4 + T cells with recombinant Fc-TL1A ( Fig. 2 ) , which indicate that TL1A expressed on APCs may promote the diff erentiation of Th17 cells. The eff ect on Th17 cells appears quite specifi c, as exogenous TL1A did not have any eff ect on T reg cell diff erentiation induced by TGF-␤ (Fig. S3 A, available at http:// www.jem.org/cgi/content/full/jem.20071364/DC1), even Because DR3 expression was observed in both n -T reg and i -T reg cells ( Fig. 1, D and E ), we also tested whether Fc-TL1A could infl uence their proliferation. As shown in Fig. 3 D , Fc-TL1A specifi cally induced the proliferation of Th17 but not n -T reg, i -T reg, or Th1 cells, suggesting that the relative expression levels of diff erent DR3 isoforms may determine the TL1A responsiveness of a given cell type.
Generation of TL1A-defi cient mice
To further understand the function of TL1A -DR3 interaction in regulating Th17 cells in vivo, a TL1A KO mouse was generated by replacing exon 4 of the TL1A ( Tnfsf15 ) locus with a neomycin cassette ( Fig. 4 A ) . Exon 4 encodes amino acids 103 -252 of TL1A, encompassing the TNF homology domain that is essential for TL1A function. Lack of TL1A expression was confi rmed by RT-PCR of kidney tissues ( Fig. 4 B ) , which contain high levels of TL1A mRNA ( 20, 35 ) . TL1A KO mice appeared phenotypically normal, and similar immune cell numbers and proportions were observed in the lymph nodes, spleen, thymus, and bone marrow ( Fig. 4 C ; trast, in the absence of TCR signaling, WT BMDCs greatly enhanced the proliferation of Th17 cells, and this enhancement eff ect was signifi cantly diminished when TL1A-defi cient BMDCs were used ( Fig. 6 A ) . Importantly, the addition of exogenous Fc-TL1A to the latter culture condition restored the enhancement eff ect ( Fig. 6 B ) , clearly demonstrating that the ability of WT BMDCs to promote antigen-independent proliferation of Th17 cells requires TL1A expression. Even in the presence of OVA peptide, the proliferation of Th1 cells stimulated by WT and TL1A-defi cient BMDCs was similar, whereas the proliferation of Th17 cells was once again reduced using TL1A-defi cient BMDCs ( Fig. 6 C ) . Interestingly, the reduced proliferation of Th17 cells in the absence though these cells also up-regulate DR3 expression. Conversely, although OT-II CD4 T cells activated by TL1A KO BMDCs exhibited reduced Th17 diff erentiation based on intracellular IL-17A staining, Foxp3 expression was not reciprocally increased (Fig. S3 B) .
Because Fc-TL1A promoted Th17 cell proliferation, we also assessed the impact of TL1A defi ciency in APCs on the expansion of diff erentiated Th17 cells. In vitro -diff erentiated Th1 and Th17 cells were either left alone or incubated with WT or TL1A-defi cient BMDCs, and their proliferation was measured by [ 3 H]thymidine incorporation at 24 h. As shown in Fig. 6 A , the proliferation of Th1 cells was not aff ected by the presence of either WT or TL1A KO BMDCs. In con- ( Fig. 3 B ) .
TL1A defi ciency results in decreased severity of EAE disease
To determine the biological signifi cance of the TL1A -DR3 pathway in vivo , we used a Th17-mediated autoimmune disease model, myelin oligodendrocyte glycoprotein (MOG)-induced EAE ( 18, 36 ) . In four independent experiments, TL1A KO and WT animals exhibited similar timing of disease onset, but TL1A KO mice consistently showed a significantly reduced disease severity, as manifested by both a lower maximal disease score and lower cumulative scores throughout the course of the disease ( Fig. 7 A and Table I ). Although no statistical signifi cance was achieved, a consistent trend toward lower disease incidence was observed in TL1A KO mice (unpublished data).
Histological examination of the spinal cords was performed to determine whether the diff erence in clinical symptoms observed between TL1A KO and WT mice correlated with the degree of infl ammatory infi ltration and demyelination in the central nervous system (CNS). TL1A KO mice exhibited fewer mononuclear infi ltrates and demyelination foci than WT control animals at day 27 after immunization ( Fig. 7 , B and C ). These results indicate that the reduced clinical scores observed in the KO animals were likely caused by decreased infl ammation and tissue damage in the CNS. Because our in vitro studies suggest that the TL1A -DR3 of TL1A was observed only when lower concentrations of OVA peptide were used ( Fig. 6 C ) . These data are consistent with our earlier results that Fc-TL1A enhanced the prolifera- clinical symptoms, and their levels peak at days 5 -7 after disease onset (unpublished data) ( 37, 38 ) . We found that the percentage of CD45 + CD4 + cells in the CNS of TL1A KO mice was consistently reduced as compared with WT animals over the course of the study ( Fig. 7, E and F ) . Absolute numbers of CD45 + CD4 + cells were also examined and showed a similar trend (unpublished data). These observations show that the eff ect of TL1A defi ciency in reducing CD4 T cell levels in the CNS is evident early in and maintained throughout the disease course. In addition, there were dramatic reductions in the total numbers of recovered CD4 + T cells expressing proinfl ammatory cytokines such as IL-17, IFN-␥ , IL-6, and TNF-␣ in day 17 CNS cell isolates ( Fig. 7 G ) .
Function of TL1A in the generation, expansion, and effector function of autoreactive T cells By signaling through its receptor DR3, TL1A could potentially contribute to the pathogenesis of autoimmune diseases at multiple levels. We fi rst tested whether TL1A defi ciency aff ects T cell priming in EAE. WT and TL1A KO mice were immunized with MOG peptide in CFA, and lymph node and spleen cells were analyzed for IL-17 and IFN-␥ expression on day 10. As shown in Fig. 8 , the percentages of IL-17 -and IFN-␥ -expressing populations were significantly decreased in TL1A KO mice. More impressively, a population of CD4 + T cells expressing both IL-17 and IFN-␥ was observed in WT mice, and was most consistently and pathway may be involved in the generation and/or function of pathogenic MOG-specifi c T cells during the course of EAE, the levels of T cell infi ltration were further quantifi ed by image analysis of anti-CD3 staining. As shown in Fig. 7 D , TL1A KO animals had fewer CD3 + cells per spinal cord cross section than WT counterparts.
Several distinct factors could potentially infl uence the degree of CNS T cell infi ltration in the context of EAE. To rule out the possibility that the lesser T cell infi ltration seen in the spinal cords of TL1A KO animals was caused by a reduced ability of their T cells to survive in the CNS, Tdt-mediated dUTP-biotin nick-end labeling and anti-activated caspase-3 staining were performed to assess the extent of apoptosis in TL1A KO and WT CNS. The level of apoptosis in the WT spinal cord was low on days 21 or 27 after immunization. Furthermore, no increase in apoptotic cells was observed in the KO spinal cords (unpublished data), suggesting that T cell apoptosis is unlikely to be a contributing factor underlying the reduced infi ltrating T cell numbers observed in the CNS of TL1A-defi cient animals with EAE.
To determine whether the reduction in CNS T cell frequency seen on day 27 was caused by diff erent temporal kinetics between WT and KO animals, levels of CD4 + T cells in the CNS (spinal cord and cerebellum) were assessed at multiple time points by fl ow cytometry. CD4 + T cells start accumulating in the CNS of WT mice 1 or 2 d before the onset of 
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To defi nitively demonstrate that Th17 cells indeed require TL1A signaling to completely exert their diseasedriving capacities in vivo, we again took advantage of the discussed adoptive transfer model of EAE, except in this case the pathogenic Th17 cells were diff erentiated and expanded in vitro under optimal IL-23 concentrations. The majority ( ‫ف‬ 66 -86%) of the resulting MOG-specifi c CD4 + T cells appeared to be IL-17 producing, based on intracellular cytokine staining, and expressed DR3, including the full-length variant 1 isoform, as confi rmed by real-time PCR analysis (Fig. S6 , available at http://www.jem.org/ cgi/content/full/jem.20071364/DC1). The in vivo role of TL1A in regulating the pathogenic functions of these largely diff erentiated Th17 cells was then assessed by examining EAE disease severities observed after adoptive transfer into either WT or TL1A KO mice. Fig. 9 clearly shows that in comparison to WT recipients, the severity of EAE disease was signifi cantly reduced in TL1A KO mice, indicating that continuous TL1A signaling is in fact required in vivo for these transferred pathogenic T cells to achieve their maximal disease-driving potential. Consistently, the numbers of IL-17, IFN-␥ , and double-producing cells were all greatly reduced in the CNS infi ltrates of TL1A KO mice ( Fig. 9 B ) . These fi ndings thus confi rm the in vivo contribution of the TL1A -DR3 pathway in regulating Th17 cell function and in promoting Th17-mediated autoimmune disease pathologies.
DISCUSSION
The recent identifi cation and characterization of Th17 lineage cells have signifi cantly advanced our understanding of the pathogenic mechanisms underlying several infl ammatory dramatically reduced in the KO animals. Similar results were obtained with MOG restimulation (Fig. S4 , available at http://www.jem.org/cgi/content/full/jem.20071364/DC1). The frequency of Foxp3 + CD4 + cells was also measured after MOG restimulation of lymph node and spleen cells, with no signifi cant diff erence found between WT and TL1A KO mice (1.74 vs. 1.92% FoxP3 + CD4 + cells, respectively; unpublished data). These results are consistent with our in vitro diff erentiation results ( Fig. 2 A and Fig. 5 ) and suggest that TL1A defi ciency impairs the priming of MOG-specifi c CD4 + T cells, which may contribute to decreased EAE severity in TL1A KO mice.
Because TL1A promoted the proliferation and diff erentiation of Th17 cells in vitro, we sought to test whether TL1A can also contribute to disease progression by expanding autoreactive T cells and/or potentiating their pathogenic eff ects in the context of EAE using an adoptive transfer model. Splenocytes and draining lymph node cells from MOGimmunized mice were expanded in vitro with MOG peptide and 5 ng/ml of suboptimal IL-23 in the presence of control Ig or Fc-TL1A. On day 10 after expansion, purifi ed CD4 + T cells were counted, and 10 million cells were adoptively transferred into recipient mice to induce EAE. Our results showed that not only were more cells recovered with Fc-TL1A treatment, but more importantly, when transferred with the same number of CD4 + T cells, mice receiving Fc-TL1A -expanded cells developed EAE disease with 100% disease incidence and a peak clinical score of 2 ( Fig. S5 A, available at http://www.jem.org/cgi/content/ full/jem.20071364/DC1), whereas mice receiving control Ig -expanded cells did not show any disease symptoms. Furthermore, when CD4 + T cells from MOG-immunized mice were expanded without IL-23, only a portion of the recipients of CD4 + T cells cultured in the presence of MOG peptide and Fc-TL1A showed minimal signs of EAE disease development, with a mean clinical score of 1.33 in aff ected mice with 60% disease incidence, whereas recipients of CD4 + T cells cultured with MOG peptide and control Ig did not show any disease symptoms (Fig. S5 B) . Therefore, these results indicate that in addition to participating in the effi cient priming of autoreactive T cells, TL1A may further contribute to T cell -mediated autoimmunity through promoting the proliferation of Th17 cells, as well as maximizing their pathogenic potential. TL1A plays a specifi c role in expanding Th17 eff ector cells even in the absence of TCR stimulation, whereas IL-17 secretion was not increased upon TL1A stimulation, suggesting that TL1A primarily supports the proliferation of Th17 cells. It is possible that IL-17 secretion upon TL1A stimulation may require additional signaling pathways, e.g., from TCR or IL-23R. In contrast, TL1A did not aff ect expansion or IFN-␥ secretion by in vitro -diff erentiated eff ector Th1 cells. Moreover, our data indicate that Th17 but not Th1 cell proliferation is supported by mature DCs independent of TCR stimulation. The signifi cance of this fi nding is unclear at this stage, but this regulation may result in the expansion of Th17 cell numbers in the infl ammatory tissues, which is important for early host defense against certain infection or infl ammatory autoimmune diseases such as EAE. The homeostatic proliferation of Th17 cells in response to mature DCs appears to be dependent on TL1A -DR3 interaction, as expansion of Th17 eff ector cells is selectively impaired in the presence of TL1A KO BMDCs. Our results suggesting the specifi c role of TL1A in Th17 effector cell expansion diff er from previous reports that TL1A promotes expansion and IFN-␥ secretion by Th1 cells. However, previous studies used mouse and human memory T cells that were generated in vivo. In addition, they did not examine the eff ect of TL1A on IL-17 or Th17 cells, nor did they demonstrate a role for endogenous TL1A in regulating IFN-␥ production ( 33 ) . At this point, it is possible that TL1A regulation of eff ector and memory cells diff ers. Additionally, TL1A-mediated eff ects on Th1 cells may require the synergistic action of additional signaling pathways such as IL-12 or IL-18 cytokines, whereas TL1A alone is suffi cient to induce Th17 proliferation ( 33 ) . Further experiments are needed to explore the diff erences in the action of TL1A on Th17 and Th1 eff ector and memory CD4 + T cells, which may shed additional light on the novel function of TL1A. and autoimmune diseases ( 3 -5, 39 ) . Compared with the considerable progress on the various pathways important for the diff erentiation of Th17 cells from naive CD4 + T cells, little is known regarding the regulatory mechanisms governing the proliferation and function of eff ector Th17 cells. In this study, we have identifi ed the TNF family ligand -receptor pairing of TL1A -DR3 as a novel regulator of Th17 cells.
TL1A, a member of the TNF superfamily, exerts its eff ects by binding and signaling through DR3 ( 19 ) . Previous studies have shown that recombinant TL1A enhances the IL-2 responsiveness of TCR-activated human CD4 + T cells and promotes IFN-␥ secretion, and synergizes with IL-12 and IL-18 in stimulating TCR-independent secretion of IFN-␥ by human PB CD4 + memory T cells ( 20, 32 ) . Additionally, mouse memory CD4 + T cells were reported to proliferate in response to TL1A stimulation, whereas naive CD4 + T cells were unresponsive ( 33 ) . However, the eff ect of TL1A on Th17 cells was Results shown are compiled from two independent experiments. Disease severity was significantly reduced in KO mice (WT vs. KO mean cumulative score, P = 0.04; and mean maximal score, P = 0.05, as determined by the Mann Whitney nonparametric test), with no difference in disease incidence (WT, 9 out of 11 mice; KO, 10 out of 12 mice). Disease onset tended to be delayed (P = 0.06, as determined by the Student ' s two-tailed t test). (B) Mononuclear infi ltrating cells from the CNS of WT and TL1A KO mice (pools of fi ve animals) at day 24 after adoptive transfer were restimulated with PMA plus ionomycin and analyzed by intracellular cytokine staining. The absolute number of IL-17 -and/or IFN-␥ -expressing CD4 + T cells are shown.
Because TL1A and DR3 have been implicated in other infl ammatory diseases ( 41 ) , targeting this pathway may be benefi cial in patients with Th17-mediated diseases.
MATERIALS AND METHODS
Mice. TL1A KO mice were generated on the 129/Sv background by a targeted deletion of exon 4 of the TL1A locus on chromosome 4C1. TL1A defi ciency was confi rmed by RT-PCR on kidney tissues previously shown to express high levels of TL1A mRNA ( 20, 35 ) . Mice were maintained at Biogen Idec or the M.D. Anderson Cancer Center animal facility in compliance with Institutional Animal Care and Use Committee (IACUC) guidelines. TL1A-defi cient mice were backcrossed onto the C57BL/6 background for 5 -10 generation for these experiments. Mice were genotyped for TL1A defi ciency using a PCR-based assay on genomic DNA from tail biopsy samples. EAE experiments were conducted with mice backcrossed to the C57BL/6 strain for 6 or 10 generations with similar results. All animal experiments were performed based on the protocol approved by the IACUCs at M.D. Anderson Cancer Center or Biogen Idec.
Gene expression analysis. Diff erentiating CD4 + T cells were harvested at the times indicated in the fi gures, RNA was prepared using TRI zol reagent (Invitrogen), and cDNA was prepared as described previously ( 10, 42 ) . Naive CD4 + T cell cDNA was used for normalization of DR3 expression. Expression of DR3 was analyzed by real-time PCR analysis using the SYBR green PCR kit (Bio-Rad Laboratories). Expression of GAPDH was used as normalization control. Primer sequences are as follows: total DR3, (sense) 
Generation of BMDCs.
Mouse hind limbs were dissected, and tibia and fi bula were fl ushed with warm RPMI 1640 medium. Red blood cells were lysed, and a single-cell suspension was cultured in RPMI 1640 medium containing GM-CSF for 7 d. Media was replaced every 2 d with fresh RPMI 1640 medium containing GM-CSF. On day 7, immature BMDCs were stimulated with 1 μ g/ml LPS overnight before being used as APCs. Percentages of BMDCs before and after activation were confi rmed by staining for CD11c, MHC class II, CD80, and CD86.
T cell diff erentiation and inducible T reg cell preparation. Naive OT-II CD4 + T cells were purifi ed from RAG KO/OT-II mice by magnetic separation using anti-CD4 magnetic beads, and a cell purity of > 97% was routinely obtained. In some experiments, CD4 + CD62L hi CD25 Ϫ naive T cells or CD4 + CD62L hi CD44 low CD25 +ve n -T reg cells were sorted from single-cell suspensions of spleens and lymph nodes by FACS. 0.5 × 10 6 OT-II cells were cultured at a 20:1 ratio with BMDCs pulsed with 10 μ g/ml OT-II peptide, or were cultured with 10 μ g/ml OT-II peptide -pulsed irradiated splenocytes at a 1:1 ratio. Additionally, for diff erentiating Th1 cells, 20 ng/ml IL-12 and 5 μ g/ml anti -IL-4 (clone 11B11) were added to the culture. For Th17 diff erentiation, 10 ng/ml mIL-1 ␤ , 5 ng/ml hTGF-␤ , 20 ng/ml mIL-6, 10 μ g/ml anti -IFN-␥ (clone XMG1.2), 5 μ g/ml anti -IL-4 (clone 11B11), and 20 ng/ml mIL-23 were added. For generating Th2 cells, 20 ng/ml IL-4 and 10 μ g/ml anti -IFN-␥ were added. For generating T reg cells, 5ng/ml hTGF-␤ (PeproTech), and 10 μ g/ml anti -IFN-␥ and anti -IL-4 were added. Percentages of T reg cells were analyzed by intracellular staining using the mouse FoxP3 staining kit according to the manufacturer ' s recommendations (eBioscience). All cytokines used were purchased from PeproTech. Human Fc-TL1A, as previously described ( 42 ), or control human Ig (Sigma-Aldrich) were added as indicated in the fi gures at 1 μ g/ml.
DR3 expression is also up-regulated in both n -T reg and i -T reg cells, consistent with the observation that TGF-␤ signaling primarily up-regulates DR3. In contrast to Th17 cells, T reg cells also up-regulate a DR3 isoform in which there is a deletion of cysteine-rich region IV in the extracellular domain (variant 3), as compared with full-length DR3 (variant 1). TL1A stimulation did not enhance the proliferation T reg cells. Our data also demonstrate that diff erentiation of T reg cells is not aff ected by TL1A recombinant protein or enhanced in the absence of TL1A signaling in vitro. In addition, we found that the percentages of FoxP3 + CD4 + cells in the lymph nodes and spleens of MOG-immunized mice were similar in WT and TL1A KO mice (unpublished data). Further studies are required to understand the function of diff erent isoforms of DR3 in T reg cells.
The physiological relevance of our fi ndings was addressed using TL1A-defi cient mice. ( 41 ) . Reduced cytokine-expressing CD4 + cells in the CNS of TL1A KO mice after disease induction supports reduced Th17 expansion in the tissue, and thereby reduced IL-17 -induced chemokine production ( 18 ) .
In summary, we show in this paper that TL1A expressed by mature DCs regulates Th17 diff erentiation, eff ector cell expansion, and function in EAE disease through its receptor DR3, which is selectively up-regulated in Th17 cells. This analysis reveals a novel and unique regulation of Th17 cells. tide (MEVGWYRSPFSRVVHLYRNGK) emulsifi ed in CFA with 400 μ g M. tuberculosis . 10 d later, the spleen and lymph nodes were collected from each individual and processed into a single-cell suspension, and stimulated with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence of 1 μ g/ml Golgi Plug for 5 h, or restimulated overnight with 50 μ g/ml of MOG peptide with Golgo Plug added during the last 5 h. Cells were treated with Fcblocking mAbs and surface stained with anti-CD4 -allophycocyanin, followed by intracellular staining with PE-conjugated mAb to IL-17 and FITC-conjugated mAb to IFN-␥ , or isotype control mAbs according to the manufacturer ' s instructions (BD Biosciences). Data were acquired using an LSRII instrument (Becton Dickinson) and analyzed using FlowJo FACS analysis software. Percentages of cytokine-expressing cells within the CD4 + population were determined after subtracting the percentages obtained with isotype control mAbs.
Isolation and analysis of CNS-infi ltrating cells. At the desired time points after EAE induction or adoptive transfer of EAE, animals were killed and perfused through the left ventricle with room temperature Ames medium (Sigma-Aldrich) or PBS to remove blood leukocytes. Spinal cords and cerebellum or whole brains were collected into ice-cold HBSS with 10% fetal bovine serum. Tissue was disrupted through a 100-μ m strainer, washed 1 × with HBSS/serum, and resuspended in 5 ml of 37% Percoll (GE Healthcare) in PBS. Gradients were underlayered with 2.5 ml of 70% Percoll in PBS and centrifuged at 2,000 g for 20 min. The mononuclear cells were collected from the 37/70 interface, washed with HBSS/serum, and processed for FACS staining. For kinetic analysis of CNS-infi ltrating T cells, cells were stained with BD Bioscience antibodies for anti-CD45 -PerCP, CD11b-allophycocyanin, and anti-CD4 -PE. For the analysis of intracellular cytokine staining, CNS-isolated WT and KO cells (pools of fi ve to six individual mice per group) were for the last 5 h with 50 ng/ml of PMA and 500 ng/ml of ionomycin in the presence of 1 μ g/ml Golgi Plug. Cells were treated with Fc-blocking mAbs and surface stained with anti-CD45 -PerCP and anti-CD4 -allophycocyanin (BD Biosciences), followed by intracellular cytokine staining with PE-conjugated mAbs to IL-17, IFN-␥ , IL-6, and TNF, a PEconjugated mAb to IL-17 and an FITC-conjugated mAb to IFN-␥ , or isotype control mAbs, according to the manufacturer ' s instructions (BD Biosciences). Data were acquired on the LSRII instrument and analyzed using the FlowJo FACS analysis software. Absolute numbers of cytokineexpressing CD4 + cells were calculated.
Statistical analysis. Statistical analysis was performed using Prism software (GraphPad), and analysis methods used are indicated in the respective fi gure legends.
Online supplemental material. Fig. S1 shows that TL1A-Ig does not induce IL-17 expression by eff ector Th17 cells. Fig. S2 provides an analysis of lymphocyte subpopulations and mononuclear cell suspensions in TL1A KO and WT spleen, lymph node, thymus, and bone marrow. We thank Bruz Marzolf for his assistance in the microarray analysis, the Biogen Idec animal facility for animal maintenance, Tom Crowell and the histology facility for tissue processing, Juanita Campos and the FACS facility for sample analysis, Leila Rieder and Norm Allaire for TaqMan PCR, and Dr. Ben Hahm and Yi Luo for technical assistance and helpful discussions.
This work was supported in part by research grants from the National Institutes of Health (to C. Dong). B.P. Pappu is an Odyssey Fellow supported by the Odyssey Program and the Theodore N. Law Endowment for Scientifi c Achievement Proliferation and cytokine measurement. In vitro -diff erentiated cells were restimulated on day 5 with a titrating dose of anti-CD3 with or without exogenous human Fc-TL1A, as described previously ( 43 ) , or control human Ig. For anti-CD3 stimulation, 96-well plates were coated with the concentration of anti-CD3 (clone 2C11) indicated in the fi gures, and 1.5 -2 × 10 5 cells were added per well. For restimulation of differentiated cells with BMDCs, OVA peptide was titrated and incubated with BMDCs, and 1.5 × 10 5 cells T cells were added at a 20:1 ratio with DCs. To measure proliferation, including naive and T reg cell experiments, 1 μ Ci [ 3 H]thymidine was added per well during the last 8 h of stimulation and harvested, and radioactive incorporation was measured by a ␤ -scintillation counter (PerkinElmer). For cytokine measurement, culture supernatant was harvested at 24 h after stimulation and analyzed by ELISA, as previously described ( 18 ) .
Intracellular cytokine staining of in vitro -diff erentiated Th cells. Differentiated Th cells were harvested on the day indicated in the fi gures, and restimulated with 50 ng PMA and 500 ng/ml ionomycin for 6 h in the presence of Golgi Plug (1 μ g/ml Brefeldin A; BD Biosciences). Cells were harvested and stained for CD4 (clone RM4-4) and fi xed with 4% paraformaldehyde. Cells were then permeabilized with Cytoperm solution (BD Biosciences), and stained with anti -mouse IL-17 (clone TC11-18H10.1) and anti -mouse IFN-␥ . At least 50,000 live events were acquired on a FACSVantage system (BD Biosciences) and analyzed using FlowJo software (Tree Star, Inc.) EAE induction. 8 -12-wk-old female C57BL/6 TL1A KO and WT animals were immunized subcutaneously with 200 μ g MOG peptide (MEVGWYRSPFSRVVHLYRNGK) emulsifi ed in CFA (Chrondex) with 200 μ g Mycobacterium tuberculosis . 50 ng of pertussis toxin (List Biological) in PBS was given i.p. at the time of immunization, and 7 -10 animals were used for each experimental group. For adoptive transfer, C57BL/6 WT mice were immunized subcutaneously with MOG peptide, as described, with 400 μ g M. tuberculosis , and 7 d later the draining lymph nodes and spleen cells from MOG-primed animals were restimulated in vitro with 25 μ g/ml MOG and 20 ng/ml rIL-23 for 7 d. 10 million CD4 + T cells purifi ed by negative selection using magnetic beads (purity > 80%) were adoptively transferred into WT or TL1A KO recipients by i.p. injection, followed by 50 ng of pertussis toxin per mouse i.p. at the time of transfer. In some experiments, cells were expanded using 25 μ g/ml MOG, and either in the presence or absence of suboptimal 5 ng/ml rIL-23 or in the presence or absence of Fc-TL1A for 10 d. CD4 + T cells were then purifi ed and adoptively transferred into C57BL/6 recipient mice i.v., followed by 500 ng/ml of pertussis toxin. Animals were monitored for weight loss and development of EAE symptoms. Disease severity was scored as follows: 0, no sign of impairment; 1, limp tail; 2, hind limb weakness; 3, hind limb paresis, or paresis of one side of the body and rolling; 4, hind limb paralysis; and 5, moribund or dead ( 44 ) .
Histological evaluation. Animals were killed, and spinal cords were fl ushed out with PBS and fi xed in 4% paraformaldehyde for 72 h. Tissue was paraffi n embedded and cross sectioned using standard protocols. Sections were stained for hematoxylin and eosin, Luxol fast blue for myelin, CD3, F4/80, Ki-67, Tdt-mediated dUTP-biotin nick-end labeling, and anti-active caspase-3 using standard procedures. Tissues were examined microscopically, and the CD3 staining was quantifi ed using the MetaMorph image analysis software (MDS Analytical Technologies). In brief, a threshold for positive brown staining was established, and the total thresholded area was determined for each spinal cord cross section (at 10 × magnifi cation). The area was divided by the mean area of brown staining corresponding to one CD3-positive cell to calculate the approximate number of CD3-positive cells per spinal cord cross section. Six spinal cord sections were analyzed per animal.
Intracellular cytokine expression in the spleen and lymph nodes after MOG immunization. 8 -12-wk-old female C57BL/6 TL1A KO and WT animals were immunized subcutaneously with 200 μ g MOG pep-
